Summary & Overview
HCPCS J7640: Formoterol Inhalation Solution, Unit Dose via DME
HCPCS Level II code J7640 denotes a compounded formoterol inhalation solution supplied in unit dose form and administered through durable medical equipment. Formoterol is a long-acting bronchodilator used in obstructive airway diseases; this code captures compounded inhalation therapy intended for delivery via DME and is relevant to DME suppliers, respiratory therapy programs, and payers overseeing pharmacy and DME benefit coordination. Nationally, accurate coding of compounded inhalation products affects claims processing, benefit assignment between pharmacy and DME, and coverage determinations for home respiratory care.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for formoterol inhalation therapy, typical sites of service, and the billing implications for compounded unit dose preparations delivered through DME. The publication also summarizes common modifier usage, payer coverage considerations where available, and areas where data was not provided.
This piece provides benchmarks and policy-oriented context for coding and billing decisions, highlights payer coverage patterns when available, and outlines the clinical and administrative details that influence reimbursement and claim adjudication for compounded inhalation DME therapies.
Billing Code Overview
HCPCS Level II code J7640 represents formoterol, inhalation solution, compounded product, administered through DME, unit dose form, 12 micrograms. This code denotes a compounded bronchodilator formulation of formoterol intended for inhalation delivery using durable medical equipment (DME) that accepts unit dose preparations.
Service type: Drug administration (inhalation medication) via durable medical equipment
Typical site of service: Home or outpatient settings where DME is used for inhalation therapy, such as patient residences with DME suppliers or outpatient infusion/respiratory therapy clinics.
Clinical & Coding Specifications
Clinical Context
A 68-year-old patient with moderate to severe chronic obstructive pulmonary disease (COPD) and frequent exertional dyspnea presents for outpatient durable medical equipment (DME) management. The patient uses a nebulizer system for bronchodilator therapy and requires a compounded unit-dose form of inhaled long-acting beta2-agonist therapy. The clinic verifies previous medication trials, documents an order for J7640 — Formoterol, inhalation solution, compounded product, administered through DME, unit dose form, 12 micrograms — and coordinates DME delivery. A respiratory therapist or home health nurse instructs the patient on nebulizer use, dose preparation, and safe disposal of unit-dose vials. The clinical workflow includes medication reconciliation, prescription generation with DME-specific instructions, prior authorization if required by the payer, delivery scheduling through the DME supplier, and post-delivery patient education and follow-up to assess symptom control and inhalation technique.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no additional modifier applies to the service. |
| 22 | Increased procedural services | Use when additional work, time, or effort for medication preparation or compounding is documented beyond typical expectation.